Eledon Pharma to Present Phase 1b Tegoprubart Kidney Transplant Data at American Transplant Congress

IRVINE, Calif., May 09, 2024 - Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) has announced its participation in the upcoming American Transplant Congress (ATC) in Philadelphia, PA, scheduled from June 1 to 5, 2024. Highlighting the event, Eledon will present a poster that showcases updated data from their continuing open-label Phase 1b trial and open-label extension study. This research focuses on the use of tegoprubart for preventing rejection in kidney transplant patients.

The poster, titled "Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant," will be presented by Steve Perrin, Ph.D., who serves as the President and Chief Scientific Officer at Eledon Pharmaceuticals. The poster will be exhibited twice on Monday, June 3, from 9:15-10:00 A.M ET and again from 2:30-3:15 P.M ET. Following the presentations, the poster will be available on the Investor section of the Eledon website.

In addition to the poster presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the ATC on Sunday, June 2, at 12:15 P.M ET. The symposium is titled "Blazing a Path Towards 'Total Success' in Solid Organ Transplantation." The faculty for this session includes notable experts such as Dr. Flavio Vincenti from the University of California San Francisco, Dr. Diane Cibrik from the University of Kansas Health System, Dr. Allan Kirk from Duke University School of Medicine, Dr. Jay Fishman from Massachusetts General Hospital, Dr. Klemens Budde from Charité Universitätsmedizin Berlin, and Dr. Roslyn Mannon from the University of Nebraska Medical Center.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies to manage and treat life-threatening conditions. Their lead investigational product, tegoprubart, is an anti-CD40L antibody. It targets the CD40 Ligand within the costimulatory CD40/CD40L cellular pathway, which is crucial for immune cell activation and function. This makes it a promising candidate for non-lymphocyte depleting, immunomodulatory therapeutic interventions.

The company is leveraging extensive historical research on anti-CD40 Ligand biology to advance preclinical and clinical studies in several key areas. These include kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon Pharmaceuticals is headquartered in Irvine, California.

Eledon Pharmaceuticals continues to innovate and explore new therapeutic avenues, strengthening its position in the biotechnology sector. Their contributions to transplant medicine and immunomodulation highlight their commitment to addressing significant medical challenges and improving patient outcomes. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!